• Clinical Pathology
    • Colorectal Caner
    • Human Molecular Genetics
    • Molecular Genetic Pathology
    • colon cancer prevention research
    • Molecular pathology
    Molecular Pathologist at the University of Washington
    Molecular Pathologist at the University of Washington

    Dr. Pritchard is an Associate Professor and head of the genetics division of Laboratory Medicine, as well as the co-director of the genetics and solid tumors laboratory at the University of Washington Medical Center that services the Seattle Cancer Care Alliance (SCCA). He completed his graduate and medical training at the University of Washington School of Medicine. The Pritchard laboratory focuses on oncology molecular diagnostics, particularly the source and utility of cell-free nucleic acid biomarkers in blood, and the development of innovative molecular diagnostics for the identification of mutations that can guide risk- assessment and therapeutic decision making. His clinical work focuses on applications of next-generation sequencing gene panels for cancer risk assessment and precision treatment. He has led the development and implementation of multiple cancer gene panel tests that are in current clinical use for cancer patients and their families. For more details about Dr. Pritchard see: For more details about the UW-OncoPlex™ program for precision medicine see:

    • Hematology and Oncology
    • Director of the Drug Development Unit, and Head of the Prostate Cancer Targeted Therapy Group at The Institute of Cancer Research
    Professor Johann de Bono is a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal Marsden. He is the Director of The Drug Development Unit, overseeing the conduct of Phase I trials, with a particular interest in innovative trial designs, circulating biomarkers and prostate cancer. He also leads the Prostate Cancer Targeted Therapy Clinical Trials Team and the Cancer Biomarkers laboratory team. He graduated from the University of Glasgow medical school in 1989, graduating as a Member of the Royal College of Physicians (MRCP) in 1992. He was awarded a four-year Cancer Research Campaign Clinical Fellowship, which allowed him to pursue a PhD between 1993 and 1997. He trained in medical oncology, and was awarded an MSc (Cancer Sciences) from Glasgow University. The Royal College of Physicians and Surgeons of Glasgow then awarded him a travelling scholarship that allowed him to pursue further research on the challenges of clinical trial design at the SWOG statistical headquarters at the Fred Hutchinson Cancer Centre in Seattle, USA in 1999. Between 2000 and 2003 he then pursued further research developing novel anti-cancer drugs at the Institute for Drug Development within the University of Texas Health Science Centre at San Antonio. In 2003, he was elected a Fellow of the Royal College of Physicians, and in 2009, he was elected as a Member of the Malta Order of Merit. Professor de Bono received the prestigious ESMO Award in 2012 and was part of the ICR/RMH team awarded the AACR Team Science Award. He also received an award from the Royal Society of Chemistry for his team’s work in developing abiraterone. Professor de Bono has been involved in the development of many novel agents, many of which are now approved drugs, functioning as chief investigator on Phase I trials such as abiraterone, olaparib and afatinib. He has served as chief investigator of multiple drugs that have changed the standard of care for prostate cancer patients including abiraterone, cabazitaxel and enzalutamide and has published more than 300 manuscripts including multiple publications in the New England Journal of Medicine and The Lancet. He has led on the study of circulating tumour cells, whole blood expression profiling and plasma DNA in metastatic prostate cancer patients and pioneered the concept of patient molecular stratification in early clinical trials in the Pharmacological Audit Trail.
    • Medical Oncology

    Himisha Beltran, MD is a medical oncologist and physician scientist at Weill Cornell Medical College with a research focus in genomics and understanding mechanisms of treatment resistance in advanced prostate cancer. She works with a multidisciplinary team towards bringing next generation molecular studies, novel biomarkers, and functionally validated drug targets into clinical application.

Powered by Medstro